Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GMTX Gemini Therapeutics	$56.27 -2.5%	$50.23	$1.16 ▼ $14.10	$2.44B	-0.12	189,291 shs	205,018 shs
IBRX ImmunityBio	$2.75 +0.2%	$2.74	$1.83 ▼ $7.48	$2.42B	0.08	6.30 million shs	5.09 million shs
MIRM Mirum Pharmaceuticals	$52.84 +1.6%	$47.77	$36.20 ▼ $54.78	$2.62B	0.97	456,600 shs	243,232 shs
STOK Stoke Therapeutics	$11.89 +1.2%	$10.76	$5.35 ▼ $16.15	$649.16M	1.14	672,604 shs	332,612 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GMTX Gemini Therapeutics	+1.46%	+8.17%	+7.50%	+39.77%	+22.41%
IBRX ImmunityBio	-5.52%	+1.11%	-10.75%	+10.48%	-56.92%
MIRM Mirum Pharmaceuticals	-2.44%	+3.40%	+4.74%	+34.14%	+31.66%
STOK Stoke Therapeutics	-2.57%	-2.16%	+1.91%	+55.42%	-19.41%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IBRX ImmunityBio	2.1419 of 5 stars	3.6	1.0	0.0	0.0	2.4	1.7	0.6
MIRM Mirum Pharmaceuticals	3.2933 of 5 stars	2.6	0.0	0.0	4.2	2.5	2.5	0.6
STOK Stoke Therapeutics	4.1098 of 5 stars	3.7	1.0	0.0	4.8	2.4	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
IBRX ImmunityBio	3.20	Buy	$12.25	346.27% Upside
MIRM Mirum Pharmaceuticals	3.13	Buy	$65.50	23.97% Upside
STOK Stoke Therapeutics	3.33	Buy	$24.75	108.16% Upside

Current Analyst Ratings Breakdown

Latest STOK, MIRM, IBRX, and GMTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/11/2025	MIRM Mirum Pharmaceuticals	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/8/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
7/1/2025	STOK Stoke Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
6/4/2025	IBRX ImmunityBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/3/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
5/28/2025	IBRX ImmunityBio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
5/20/2025	IBRX ImmunityBio	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$4.25 ➝ $5.00
5/19/2025	MIRM Mirum Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$73.00
5/14/2025	STOK Stoke Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/14/2025	STOK Stoke Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$47.00 ➝ $35.00
5/13/2025	MIRM Mirum Pharmaceuticals	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Strong-Buy ➝ Strong-Buy

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
IBRX ImmunityBio	$14.74M	164.37	N/A	N/A	($0.57) per share	-4.82
MIRM Mirum Pharmaceuticals	$336.89M	7.77	N/A	N/A	$4.70 per share	11.24
STOK Stoke Therapeutics	$190.91M	3.40	N/A	N/A	$4.32 per share	2.75

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
IBRX ImmunityBio	-$413.56M	-$0.58	N/A	N/A	N/A	-1,310.30%	N/A	-121.88%	8/11/2025 (Estimated)
MIRM Mirum Pharmaceuticals	-$87.94M	-$1.61	N/A	N/A	N/A	-20.39%	-33.63%	-11.50%	8/6/2025 (Estimated)
STOK Stoke Therapeutics	-$88.98M	$0.79	15.05	N/A	N/A	26.33%	19.08%	15.72%	8/6/2025 (Estimated)

Latest STOK, MIRM, IBRX, and GMTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	IBRX ImmunityBio	-$0.10	N/A	N/A	N/A	$21.95 million	N/A
8/6/2025	Q2 2025	MIRM Mirum Pharmaceuticals	-$0.31	N/A	N/A	N/A	$107.91 million	N/A
8/6/2025	Q2 2025	STOK Stoke Therapeutics	-$0.0905	N/A	N/A	N/A	$31.51 million	N/A
5/14/2025	Q1 2025	MIRM Mirum Pharmaceuticals	-$0.35	-$0.30	+$0.05	-$0.30	$98.47 million	$111.59 million
5/12/2025	Q1 2025	IBRX ImmunityBio	-$0.12	-$0.15	-$0.03	-$0.15	$17.50 million	$16.52 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
STOK Stoke Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GMTX Gemini Therapeutics	N/A	71.49	71.49
IBRX ImmunityBio	N/A	2.22	2.05
MIRM Mirum Pharmaceuticals	1.32	3.22	3.04
STOK Stoke Therapeutics	N/A	8.41	8.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GMTX Gemini Therapeutics	75.42%
IBRX ImmunityBio	8.58%
MIRM Mirum Pharmaceuticals	N/A
STOK Stoke Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
GMTX Gemini Therapeutics	12.90%
IBRX ImmunityBio	76.79%
MIRM Mirum Pharmaceuticals	22.87%
STOK Stoke Therapeutics	9.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
IBRX ImmunityBio	590	882.62 million	204.86 million	Optionable
MIRM Mirum Pharmaceuticals	140	49.53 million	38.21 million	Optionable
STOK Stoke Therapeutics	100	54.60 million	49.41 million	Optionable

STOK, MIRM, IBRX, and GMTX Headlines

Recent News About These Companies

Epilepsy Pipeline Appears Robust With 75+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

July 15 at 10:23 PM | theglobeandmail.com

Stoke Therapeutics (NASDAQ:STOK) investors are sitting on a loss of 58% if they invested five years ago

July 15 at 10:37 AM | finance.yahoo.com

The charming Stoke-on-Trent four-bed family home that's 'ready to be lived in'

July 13 at 9:30 PM | msn.com

New Royal Stoke technology cuts hospital stays by over a day

July 13 at 9:30 PM | msn.com

Stoke City Boss Delighted To Finally Get Signing Over The Line

July 13 at 6:47 AM | therealefl.co.ukT

Grit bin raiders and double parking hinders work to keep Stoke-on-Trent moving in winter

July 13 at 6:47 AM | msn.com

Five of the best beer gardens around Stoke-on-Trent to enjoy in the sun

July 13 at 6:47 AM | msn.com

Man City prospect told to gain notoriety at Stoke City

July 13 at 6:47 AM | msn.com

Case builds for Biogen, Stoke's Dravet syndrome drug

July 11, 2025 | pharmaphorum.comP

Lille rival Aston Villa in race for Stoke’s Sol Sidibé

July 10, 2025 | sports.yahoo.com

Aston Villa want Stoke City midfielder Sol Sidibe

July 10, 2025 | sports.yahoo.com

Stoke City vs Shrewsbury LIVE Score Updates: Match Canceled

July 10, 2025 | vavel.comV

Council still against Stoke-on-Trent 'merger' as devolution decision gets nearer

July 10, 2025 | msn.com

Live updates after 'accident' on Stoke-on-Trent road

July 10, 2025 | stokesentinel.co.ukS

Stoke City close in on fourth summer signing

July 10, 2025 | msn.com

Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

July 10, 2025 | globenewswire.com

Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

July 10, 2025 | businesswire.com

Live updates as firefighters on scene of Stoke-on-Trent blaze

July 8, 2025 | stokesentinel.co.ukS

Police helicopter tracks 4 masked kids on stolen motorbikes in Stoke-on-Trent park

July 8, 2025 | msn.com

Stoke-on-Trent firm collapses into administration

July 8, 2025 | msn.com

Stoke Therapeutics' (STOK) "Buy" Rating Reaffirmed at Needham & Company LLC

July 1, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

STOK, MIRM, IBRX, and GMTX Company Descriptions

Gemini Therapeutics NASDAQ:GMTX

$56.27 -1.47 (-2.55%)

As of 07/15/2025

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

ImmunityBio NASDAQ:IBRX

$2.74 +0.01 (+0.18%)

As of 03:49 PM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Mirum Pharmaceuticals NASDAQ:MIRM

$52.84 +0.86 (+1.64%)

As of 03:49 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Stoke Therapeutics NASDAQ:STOK

$11.89 +0.14 (+1.19%)

As of 03:49 PM Eastern

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time